Beyond Ozempic: Why Silicon Valley Is Turning to Experimental Peptides

Jasmine Sun on unregulated peptides moving from fringe biohacking to Silicon Valley mainstream, promising healing, focus, and optimization with little oversight

Tuesday, Jan 27, 2026

More Videos

SpaceX Takes Center Stage as Wall Street Eyes the Next Big Market Catalyst

Phil Rosen, Chief Market Strategist at ProCap Financial, discusses the growing anticipation around a SpaceX IPO and Oracle's AI-driven growth.

The Race to Build America’s Drone Delivery Network Is Officially Underway

Matternet CEO Andreas Raptopoulos discusses the future of drone delivery, U.S. manufacturing, FAA regulations and industry competition.

How the World Cup Became the Biggest AI Sports Event In History

The 2026 FIFA World Cup is deploying the largest live AI system ever used in professional sports. We go inside the tech with the man running it.

Who Will Control the Future of Driverless Cars?

Seth Goldstein, Senior Equity Analyst and Chair of the Electric Vehicle Committee at Morningstar, breaks down the robotaxi race and EV adoption trends.

Why the Next Space Revolution May Be About Power, Not Rockets

Andrew Rush, CEO of Star Catcher Industries, joins us to discuss how wireless power transmission could reshape satellite technology and space communications.

DuckDuckGo's No-AI Option Is Taking Off: Here's Why

As demand grows for AI-free search results, TechCrunch Senior Reporter Rebecca Bellan joins us to discuss DuckDuckGo's no-AI option and what it reveals.

How Siri Is About to Get a Whole Lot Smarter

Apple unveils a smarter Siri and major AI updates. Mark Spoonauer, Global Editor-in-Chief at Tom’s Guide, breaks down WWDC 2026.

How to Build a Career That Survives the AI Revolution

As AI reshapes the workforce, author Benjamin Todd explains how graduates can build resilient, fulfilling careers and thrive in a changing job market.